Literature DB >> 27357812

GGNBP2 acts as a tumor suppressor by inhibiting estrogen receptor α activity in breast cancer cells.

Zi-Jian Lan1, YunHui Hu2, Sheng Zhang2, Xian Li3, Huaxin Zhou4, Jixiang Ding4, Carolyn M Klinge5, Brandie N Radde5, Austin J Cooney6, Jin Zhang7, Zhenmin Lei8.   

Abstract

Gametogenetin-binding protein 2 (GGNBP2) is encoded in human chromosome 17q12-q23, a region known as a breast and ovarian cancer susceptibility locus. GGNBP2, also referred to ZFP403, has a single C2H2 zinc finger and a consensus LxxLL nuclear receptor-binding motif. Here, we demonstrate that GGNBP2 expression is reduced in primary human breast tumors and in breast cancer cell lines, including T47D, MCF-7, LCC9, LY2, and MDA-MB-231 compared with normal, immortalized estrogen receptor α (ERα) negative MCF-10A and MCF10F breast epithelial cells. Overexpression of GGNBP2 inhibits the proliferation of T47D and MCF-7 ERα positive breast cancer cells without affecting MCF-10A and MCF10F. Stable GGNBP2 overexpression in T47D cells inhibits 17β-estradiol (E2)-stimulated proliferation as well as migration, invasion, anchorage-independent growth in vitro, and xenograft tumor growth in mice. We further demonstrate that GGNBP2 protein physically interacts with ERα, inhibits E2-induced activation of estrogen response element-driven reporter activity, and attenuates ER target gene expression in T47D cells. In summary, our in vitro and in vivo findings suggest that GGNBP2 is a novel breast cancer tumor suppressor functioning as a nuclear receptor corepressor to inhibit ERα activity and tumorigenesis.

Entities:  

Keywords:  Breast cancer; ERα; GGNBP2; Tumor suppressor; Tumorigenesis

Mesh:

Substances:

Year:  2016        PMID: 27357812     DOI: 10.1007/s10549-016-3880-2

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  8 in total

1.  GGN Promotes Tumorigenesis by Regulating Proliferation and Apoptosis in Colorectal Cancer.

Authors:  Zheng Liu; Ming Yang; Song Wang; Hai-Peng Chen; Xu Guan; Zhi-Xun Zhao; Zheng Jiang; Ji-Chuan Quan; Run-Kun Yang; Xi-Shan Wang
Journal:  Pathol Oncol Res       Date:  2019-02-05       Impact factor: 3.201

2.  Fbxo45 promotes the malignant development of esophageal squamous cell carcinoma by targeting GGNBP2 for ubiquitination and degradation.

Authors:  Qi Wang; Linhui Wu; Ruoxue Cao; Jing Gao; Damin Chai; Yanzi Qin; Li Ma; Shiwu Wu; Yisheng Tao; Jia Ma; Zhi-Wei Wang
Journal:  Oncogene       Date:  2022-09-20       Impact factor: 8.756

3.  GGNBP2 is necessary for testis morphology and sperm development.

Authors:  Anqi Chen; Jixi Li; Lesheng Song; Chaoneng Ji; Marion Böing; Jinzhong Chen; Beate Brand-Saberi
Journal:  Sci Rep       Date:  2017-06-07       Impact factor: 4.379

4.  Estrogen and progesterone promote breast cancer cell proliferation by inducing cyclin G1 expression.

Authors:  J-M Tian; B Ran; C-L Zhang; D-M Yan; X-H Li
Journal:  Braz J Med Biol Res       Date:  2018-01-23       Impact factor: 2.590

5.  Ablation of Ggnbp2 impairs meiotic DNA double-strand break repair during spermatogenesis in mice.

Authors:  Kaimin Guo; Yan He; Lingyun Liu; Zuowen Liang; Xian Li; Lu Cai; Zi-Jian Lan; Junmei Zhou; Hongliang Wang; Zhenmin Lei
Journal:  J Cell Mol Med       Date:  2018-07-28       Impact factor: 5.310

6.  Genome-wide genetic links between amyotrophic lateral sclerosis and autoimmune diseases.

Authors:  Chun Yu Li; Tian Mi Yang; Ru Wei Ou; Qian Qian Wei; Hui Fang Shang
Journal:  BMC Med       Date:  2021-02-05       Impact factor: 8.775

7.  Effects of zinc finger protein 403 on the proliferation, migration and invasion abilities of prostate cancer cells.

Authors:  Xintong Xu; Zhihui Zhu; Yipeng Xu; Shasha Tian; Yingjun Jiang; Huajun Zhao
Journal:  Oncol Rep       Date:  2020-10-01       Impact factor: 3.906

Review 8.  Amyotrophic Lateral Sclerosis: A Diet Review.

Authors:  Salvatore D'Antona; Martina Caramenti; Danilo Porro; Isabella Castiglioni; Claudia Cava
Journal:  Foods       Date:  2021-12-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.